Skip to content

Clinical study of neuroimaging guided TMS treatment for depression

Clinical study of neuroimaging guided TMS treatment for depression

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078768
Enrollment
Unknown
Registered
2023-12-18
Start date
2023-12-31
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

SAINT group:Stimulation target: the area within the DLPFC with the most negative brain functional connectivity with the the subgenular anterior cingulate cortex (sgACC). Treatment parameters: iTBS mod

Sponsors

West China Xiamen Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: ? Age between 18–60 years; ? Right-hand dominant; ? Diagnosed with MDD according to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorder (DSM-5); ? Hamilton Rating Scale for Depression-17 item (HAMD-17) total score more than 18; ? Maintain a stable dose of antidepressant medication treatment for at least 4 weeks before enrollment, and unchanged throughout the entire study period; ? Volunteer to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: ? Physical diseases: endocrine system diseases such as hyperthyroidism, hypothyroidism or diabetes; ? Organic brain diseases: birth injury, trauma, encephalitis, tumors, etc Peripheral nerve and muscle system lesions; ? Suffering from other mental illnesses such as schizophrenia and obsessive-compulsive disorder; ? Have a history of mania or hypomania in the past; ? Recently taken drugs that may cause emotional disorders, such as Levofloxacin; ? History of alcohol abuse or psychoactive substance abuse; ? Pregnant or lactating women There are contraindications to the use of TMS, such as a history of epilepsy or individuals with intracranial metal implants.

Design outcomes

Primary

MeasureTime frame
the score of HAMD-17;

Secondary

MeasureTime frame
the score of HAMA;the score of MARDS;the score of C-SSRS;the score of CGI-S;the score of PSQI;the score of BDI-II;

Countries

China

Contacts

Public ContactZheng Zhong

West China Xiamen Hospital of Sichuan University

zhengzhong1963@163.com+86 189 8060 1861

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026